Spero Therapeutics to Present Company Update and Report Fourth Quarter and Full-Year 2020 Monetary Success on Thursday, March 11, 2021

CAMBRIDGE, Mass., March 03, 2021 (World NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical corporation centered on identifying, building and commercializing therapies in significant unmet want areas involving multi-drug resistant bacterial bacterial infections and uncommon health conditions, nowadays introduced that it will host a convention call and reside audio webcast on March 11, 2021 at 4:30 p.m. EST to report its fourth quarter and complete-year 2020 economic success and deliver an update on its small business and pipeline.

To obtain the get in touch with, you should dial (877) 705-6003 (domestic) or (201) 493-6725 (worldwide) and refer to conference ID 13716494. The audio webcast can be accessed under “Events and Presentations” in the Investor and Media area of the Company’s internet site at www.sperotherapeutics.com. The archived webcast will also be offered on Spero’s website for 30 days pursuing the simply call.

About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, scientific-stage biopharmaceutical company focused on determining, developing and commercializing novel solutions for multi-drug-resistant (MDR) bacterial infections and unusual disorders.

Spero’s direct solution prospect, tebipenem HBr (tebipenem pivoxil hydrobromide formerly SPR994), is being created as the initial oral carbapenem antibiotic for use in complicated urinary tract bacterial infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero introduced good prime-line results from its Stage 3 ADAPT-PO scientific demo of tebipenem HBr in cUTI and AP.

Spero is also developing SPR720, its novel oral remedy product or service applicant staying formulated for the therapy of rare, orphan pulmonary disease triggered by non-tuberculous mycobacterial (NTM) bacterial infections.

Spero also has an IV-administered upcoming generation polymyxin item prospect, SPR206, created from its potentiator system that is becoming produced to handle MDR Gram-destructive bacterial infections in the hospital location.

Story carries on

For far more info, stop by https://sperotherapeutics.com.

Spero Investor and Media Call:
Sharon Klahre
Vice President, Trader Relations
857-242-1547
[email protected]